Jafrin Jobayer Sonju

Mr. Jafrin Jobayer Sonju

Graduate Research Assistant, College of Pharmaceutical and Toxicological Sciences, University of Louisiana at Monroe
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Journal of Controlled Release
Verified
Journal Article
Closed access
JSJafrin Jobayer Sonju
Jafrin Jobayer Sonju
ADAchyut Dahal
Achyut Dahal
SSSitanshu S. Singh
Sitanshu S. Singh
SJSeetharama Jois
Seetharama Jois

6 March 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
HNHimgauri Naik
Himgauri Naik
JSJafrin Jobayer Sonju
Jafrin Jobayer Sonju
SSSitanshu Sekhar Singh
Sitanshu Sekhar Singh
ICIoulia Chatzistamou
Ioulia Chatzistamou
LSLeeza Shrestha
Leeza Shrestha
SJSeetharama Jois
Seetharama Jois
The therapeutic index of chemotherapeutic agents can be improved by the use of nano-carrier-mediated chemotherapeutic delivery. Ligand-targeted drug delivery can be used to achieve selective and specific delivery of chemotherapeutic agents to cancer cells. In this study, we prepared a peptidomimetic conjugate (SA-5)-tagged doxorubicin (Dox) incorporated liposome (LP) formulation (SA-5-Dox-LP) to evaluate the targeted delivery potential of SA-5 in human epidermal growth factor receptor-2 (HER2) overexpressed non-small-cell lung cancer (NSCLC) and breast cancer cell lines. The liposome was prepared using thin lipid film hydration and was characterized for particle size, encapsulation efficiency, cell viability, and targeted cellular uptake. In vivo evaluation of the liposomal formulation was performed in a mice model of NSCLC. The cell viability studies revealed that targeted SA-5-Dox-LP showed better antiproliferative activity than non-targeted Dox liposomes (Dox-LP). HER2-targeted liposome delivery showed selective cellular uptake compared to non-targeted liposomes on cancer cells. In vitro drug release studies indicated that Dox was released slowly from the formulations over 24 h, and there was no difference in Dox release between Dox-LP formulation and SA-5-Dox-LP formulation. In vivo studies in an NSCLC model of mice indicated that SA-5-Dox-LP could reduce the lung tumors significantly compared to vehicle control and Dox. In conclusion, this study demonstrated that the SA-5-Dox-LP liposome has the potential to increase therapeutic efficiency and targeted delivery of Dox in HER2 overexpressing cancer.

17 May 2020 in Medicine in Drug Discovery
Verified
Journal Article
Open access
MUMohammad A. Uddin
Mohammad A. Uddin
KKKhadeja-Tul Kubra
Khadeja-Tul Kubra
JSJafrin Jobayer Sonju
Jafrin Jobayer Sonju
MAMohammad S. Akhter
Mohammad S. Akhter
JSJois Seetharama
Jois Seetharama
NBNektarios Barabutis
Nektarios Barabutis
Inhibition of Hsp90 is associated with anti-inflammatory effects. We employed human lung microvascular endothelial cells to investigate the effects of the Hsp90 inhibitors 17-AAG, AUY-922 and 17-DMAG in the unfolded protein response (UPR) and viability of lung cells. Our observations indicate that moderate doses of those compounds trigger the activation of the UPR without inducing lethal effects in vitro. Indeed, AUY-922 triggered UPR activation in the lungs of C57BL/6 mice. UPR has been previously involved in the enhancement of the lung endothelial barrier function. Thus, the present study suggests that the barrier protective effects of Hsp90 inhibition in the lung microvasculature are highly probable to be associated with the activation of the UPR. Hence, the development of novel compounds which stochastically capacitate the repairing elements of UPR, may deliver new therapeutic possibilities against the severities of the acute respiratory distress syndrome.

18 May 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
ATAfsana Tajmim
Afsana Tajmim
ACARELI CUEVAS-OCAMPO
ARELI CUEVAS-OCAMPO
ASAbu Siddique
Abu Siddique
MQMohammed Qusa
Mohammed Qusa
JKJudy Ann King
Judy Ann King
Khalid El SayedKhalid El Sayed
Khalid El Sayed
Alzheimer’s disease (AD) is a complex progressive neurodegenerative disorder affecting humans mainly through the deposition of Aβ-amyloid (Aβ) fibrils and accumulation of neurofibrillary tangles in the brain. Currently available AD treatments only exhibit symptomatic relief but do not generally intervene with the amyloid and tau pathologies. The extra-virgin olive oil (EVOO) monophenolic secoiridoid S-(–)-oleocanthal (OC) showed anti-inflammatory activity through COX system inhibition with potency comparable to the standard non-steroidal anti-inflammatory drug (NSAID) like ibuprofen. OC also showed positive in vitro, in vivo, and clinical therapeutic effects against cardiovascular diseases, many malignancies, and AD. Due to its pungent, astringent, and irritant taste, OC should be formulated in acceptable dosage form before its oral use as a potential nutraceutical. The objective of this study is to develop new OC oral formulations, assess whether they maintained OC activity on the attenuation of β-amyloid pathology in a 5xFAD mouse model upon 4-month oral dosing use. Exploration of potential OC formulations underlying molecular mechanism is also within this study scope. OC powder formulation (OC-PF) and OC-solid dispersion formulation with erythritol (OC-SD) were prepared and characterized using FT-IR spectroscopy, powder X-ray diffraction, and scanning electron microscopy (ScEM) analyses. Both formulations showed an improved OC dissolution profile. OC-PF and OC-SD improved memory deficits of 5xFAD mice in behavioral studies. OC-PF and OC-SD exhibited significant attenuation of the accumulation of Aβ plaques and tau phosphorylation in the brain of 5xFAD female mice. Both formulations markedly suppressed C3AR1 (complement component 3a receptor 1) activity by targeting the downstream marker STAT3. Collectively, these results demonstrate the potential for the application of OC-PF as a prospective nutraceutical or dietary supplement to control the progression of amyloid pathogenesis associated with AD.

1 July 2021 in Coronaviruses
Verified
Journal Article
Open access
PDF file
JSJafrin Jobayer Sonju
Jafrin Jobayer Sonju
RARafi Anwar
Rafi Anwar
AAAbul Azad
Abul Azad
USUmme Habiba Sultana
Umme Habiba Sultana
KNKumar Kulldeep Niloy
Kumar Kulldeep Niloy
SDSajan Das
Sajan Das
: diseases initiated by Coronavirus (CoV) have become the major public health problems worldwide in the last two decades. The recent emergence of the deadly COVID-19 due to SARS-CoV-2 has created unprecedented pandemic situations around the globe making the need for antiviral molecules to treat it. Encountering the health conditions of the patients with synthetic molecules has shown some unpredictable results, including side effects. To face this complex situation, natural products can be good sources of enormous treatment options with fewer side effects. Wide diversity, easy availability, and a good number of scientific researches on Asian origin natural products can be a great tool to meet this critical situation. This paper reviews the currently available Asian natural products with potential antiviral effects on CoV. It includes the potential natural products of whole plant extract, partial plant extract, isolated pure compounds, and isolated pure set of compounds. Besides, the available information of in vitro and in silico from very recent papers are also summarized for the ease of future research. As a rapid search for a potential anti-CoV therapy is undergoing, Asian natural products will provide promising results but still, there are many challenges in front of us, including the robust in vitro assay to confirm the antiviral property, toxicity analysis, and fulfillment of regulatory needs. The use of appropriate natural products with the potential for a safe and more effective anti-CoV property requires multidisciplinary research with preclinical and clinical researchers, which will improve their clinical applications.